TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact covid19@trialstat.com to learn more about this program.

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!

Our Latest COVID-19 Research News

We Thought It Was Just a Respiratory Virus

Excerpt from the article: “In late January, when hospitals in the United States confirmed the presence of the novel coronavirus, health workers knew to watch for precisely three symptoms: fever, cough, and shortness of breath. But as the number of infections climbed, the symptom list began to grow. Some patients lost their sense of smell…
Read More

San Diego’s Truvian enters COVID-19 testing game with low-cost kit that delivers results in 10 minutes

Excerpt from the Article: “San Diego start-up Truvian Sciences has received federal emergency approval for a blood test that detects COVID-19 antibodies in as little as 10 minutes. Called Easy Check, the portable test will be sold by Truvian to health professionals for about $15 and has an accuracy rate in excess of 98 percent,…
Read More

Inovio stock surges after experimental Covid-19 vaccine shows long-term protection in animals

Excerpt from the article: “Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination. The stock was up more than 6% to $20.73 per share at Thursday’s close.…
Read More

Single-shot COVID-19 vaccine proves successful with primates

Excerpt from the article: “A single-shot vaccine for COVID-19 being developed by a group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, has proven successful in tests on primates and could begin phase 3 trials as early as September. The results of the tests on the vaccine, developed at…
Read More

Selva Therapeutics Announces $3 Million Series A Financing to Advance a Novel Broad Spectrum Antiviral for Infectious Diseases, Including COVID-19

Excerpt from the Press Release: “SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the…
Read More

PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

Excerpt from the Press Release: “WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP®/DELFIA® platform, enabling processing of up to 5,000 samples per day. The finger-prick sample collection device allows for…
Read More

Two COVID-19 Clinical Trials Seek to Enroll Pregnant Women

From The Scientist comes this exciting new development in clinical research into COVID-19: “Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers. As a translational infectious disease researcher at the University of Pennsylvania Perelman School…
Read More

Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line

Excerpt from the Press Release: “WAKEFIELD, MA – July 20, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing laboratory testing being conducted at a U.S. Regional Biocontainment Laboratory (RBL). The data is helping to inform the planned Phase 2 clinical trial of Brilacidin…
Read More

‘Planning to vaccinate everyone in the US,’ Moderna outlines efforts to supply their Covid-19 vaccine as manufacturing ramps up ahead of PhIII

Excerpt from the article: “Twelve days from the planned start of their Phase III pivotal trial, the executive crew at Moderna has set up the manufacturing base needed to begin production of the first 500,000 doses of their Covid-19 vaccine with plans to feed it into a global supply chain. But the initial batches will…
Read More

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

Excerpt from the Press Release: “SAN DIEGO, July 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study…
Read More

Centivax Antibody Effective in Reducing COVID-19 Lung Damage, Virus Levels and Symptoms as Both Therapeutic and Preventative in Healthy and Immunocompromised Hamsters; Confirmed by Multiple National Laboratories

Excerpt from the press release: “SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today that their antibody therapeutic protects hamsters from SARS-CoV-2, the COVID-19-causing coronavirus. Confirmed simultaneously at two independent national laboratories, these results provide critical support for the antibody to move to clinical studies to…
Read More

‘Breakthrough’ treatment slashes coronavirus death risk: UK study

Excerpt from the article: “An aerosol-based drug treatment could drastically reduce the number of new coronavirus patients dying from the disease or requiring intensive care, according to preliminary results released by a British biotech firm. In a randomised trial of 100 patients admitted to hospital with COVID-19, those who received an inhaled formula of the…
Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?